Welcome to our dedicated page for Harvard Ave news (Ticker: HAVAU), a resource for investors and traders seeking the latest updates and insights on Harvard Ave stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Harvard Ave's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Harvard Ave's position in the market.
Harvard Ave Acquisition Corporation (Nasdaq: HAVAU) priced an initial public offering of 14,500,000 units at $10.00 per unit, raising gross proceeds of $145,000,000. Units are expected to begin trading on Nasdaq under HAVAU on October 23, 2025, and the offering is expected to close on October 24, 2025, subject to customary closing conditions.
Each unit contains one Class A ordinary share and one right to receive one‑tenth of a Class A share; when separated, shares and rights are expected to trade as HAVA and HAVAR. The underwriter has a 45‑day option to purchase up to 2,175,000 additional units to cover over‑allotments. The company is a Cayman Islands blank check company seeking a business combination.
